Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Pfeiler, G; Stöger, H; Dubsky, P; Mlineritsch, B; Singer, C; Balic, M; Fitzal, F; Moik, M; Kwasny, W; Selim, U; Renner, K; Ploner, F; Steger, GG; Seifert, M; Hofbauer, F; Sandbichler, P; Samonigg, H; Jakesz, R; Greil, R; Fesl, C; Gnant, M; ABCSG.
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Br J Cancer. 2013; 108(7):1408-1414 Doi: 10.1038/bjc.2013.114 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Balic Marija
Ploner Ferdinand
Samonigg Hellmut
Stöger Herbert
Study Group Mitglieder der Med Uni Graz:
Hofmann Guenter

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship between BMI and the efficacy of tamoxifen is conflicting. We investigated the impact of BMI on the efficacy of single tamoxifen and tamoxifen plus an aromatase inhibitor in the well-defined prospective study population of the ABCSG-06 trial. ABCSG-06 investigated the efficacy of tamoxifen vs tamoxifen plus aminoglutethimide in postmenopausal women with hormone receptor-positive breast cancer. Taking BMI at baseline, patients were classified as normal weight (BMI=18.5-24.9 kg m(-)(2)), overweight (BMI=25-29.9 kg m(-)(2)), and obese (30 kg m(-)(2)) according to WHO criteria. Overweight+obese patients had an increased risk for distant recurrences (hazard ratio (HR): 1.51; Cox P=0·018) and a worse overall survival (OS; HR: 1·49; Cox P=0·052) compared with normal weight patients. Analysing patients treated with single tamoxifen only, no difference between overweight+obese patients and normal weight patients regarding distant recurrence-free survival (HR: 1.35; Cox P=0·24) and OS (HR: 0.99; Cox P=0·97) could be observed. In contrast, in the group of patients treated with the combination of tamoxifen plus aminoglutethimide, overweight+obese patients had an increased risk for distant recurrences (1.67; Cox P=0·03) and a worse OS (1.47; Cox P=0·11) compared with normal weight patients. BMI impacts on the efficacy of aromatase inhibitor-based treatment but not single tamoxifen.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged, 80 and over -
Aminoglutethimide - administration & dosage
Aminoglutethimide - adverse effects
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Aromatase Inhibitors - administration & dosage
Aromatase Inhibitors - adverse effects
Body Mass Index -
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - physiopathology
Female -
Humans -
Middle Aged -
Overweight - physiopathology
Postmenopause -
Prospective Studies -
Receptors, Cell Surface - biosynthesis
Tamoxifen - administration & dosage
Tamoxifen - adverse effects
Tamoxifen - therapeutic use
Treatment Outcome -

Find related publications in this database (Keywords)
breast cancer
aromatase inhibitor
© Med Uni Graz Impressum